(NASDAQ: ACIU) Ac Immune Sa's forecast annual revenue growth rate of 171.36% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.08%, and it is also forecast to beat the US market's average forecast revenue growth rate of 22.74%.
Ac Immune Sa's revenue in 2025 is $5,397,530.On average, 5 Wall Street analysts forecast ACIU's revenue for 2026 to be $3,370,051,902, with the lowest ACIU revenue forecast at $320,438,442, and the highest ACIU revenue forecast at $9,534,456,162. On average, 4 Wall Street analysts forecast ACIU's revenue for 2027 to be $9,072,564,730, with the lowest ACIU revenue forecast at $8,157,256,939, and the highest ACIU revenue forecast at $9,938,939,069.
In 2028, ACIU is forecast to generate $10,071,109,837 in revenue, with the lowest revenue forecast at $197,348,108 and the highest revenue forecast at $20,522,790,772.